McLeod D - Search Results

1

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer.

Simmons CE, Brezden-Masley C, McCarthy J, McLeod D, Joy AA. Simmons CE, et al. Among authors: mcleod d. Ther Adv Med Oncol. 2020 Mar 20;12:1758835920909091. doi: 10.1177/1758835920909091. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33014143 Free PMC article. Review.

2

Targeting triple-negative breast cancer: optimising therapeutic outcomes.

Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Gelmon K, et al. Among authors: mcleod d. Ann Oncol. 2012 Sep;23(9):2223-2234. doi: 10.1093/annonc/mds067. Epub 2012 Apr 19. Ann Oncol. 2012. PMID: 22517820 Free article. Review.

3

HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.

Verma S, Joy AA, Rayson D, McLeod D, Brezden-Masley C, Boileau JF, Gelmon KA. Verma S, et al. Among authors: mcleod d. Oncologist. 2013;18(11):1153-66. doi: 10.1634/theoncologist.2013-0217. Epub 2013 Nov 8. Oncologist. 2013. PMID: 24212500 Free PMC article. Review.

4

Patterns in target-directed breast cancer research.

Torres S, Simmons C, Boileau JF, McLeod D, Martins I, Trudeau M. Torres S, et al. Among authors: mcleod d. Springerplus. 2016 Feb 1;5:109. doi: 10.1186/s40064-016-1736-1. eCollection 2016. Springerplus. 2016. PMID: 26877907 Free PMC article.

5

Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.

Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V. Melosky B, et al. Among authors: mcleod d. J Clin Oncol. 2016 May 10;34(14):1676-88. doi: 10.1200/JCO.2015.63.8049. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884577 Review.

6

Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.

Pritchard KI, Chia SK, Simmons C, McLeod D, Paterson A, Provencher L, Rayson D. Pritchard KI, et al. Among authors: mcleod d. Oncologist. 2017 Jan;22(1):12-24. doi: 10.1634/theoncologist.2016-0185. Epub 2016 Nov 18. Oncologist. 2017. PMID: 27864574 Free PMC article.

7

Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.

Melosky B, Juergens R, McLeod D, Leighl N, Brade A, Card PB, Chu Q. Melosky B, et al. Among authors: mcleod d. Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29. Lung Cancer. 2019. PMID: 31319991 Review.

8

Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.

Melosky B, Cheema PK, Brade A, McLeod D, Liu G, Price PW, Jao K, Schellenberg DD, Juergens R, Leighl N, Chu Q. Melosky B, et al. Among authors: mcleod d. Oncologist. 2020 Nov;25(11):981-992. doi: 10.1634/theoncologist.2020-0193. Epub 2020 Sep 23. Oncologist. 2020. PMID: 32860288 Free PMC article. Review.

9

Canadian consensus on TRK-inhibitor therapy for NTRK fusion-positive sarcoma.

Simmons C, Deyell RJ, MacNeill AJ, Vera-Badillo FE, Smrke A, Abdul Razak AR, Banerji S, McLeod D, Noujaim J. Simmons C, et al. Among authors: mcleod d. Int J Cancer. 2021 Nov 1;149(9):1691-1704. doi: 10.1002/ijc.33723. Epub 2021 Aug 4. Int J Cancer. 2021. PMID: 34213775 Free article.

10

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.

Melosky B, Cheema P, Juergens RA, Leighl NB, Liu G, Wheatley-Price P, Sacher A, Snow S, Tsao MS, McLeod D, Chu Q. Melosky B, et al. Among authors: mcleod d. Ther Adv Med Oncol. 2021 Nov 15;13:17588359211056306. doi: 10.1177/17588359211056306. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34804219 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,395 results

Search Page